Category: CannabisNewsWire Release

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments

  • Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness
  • Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medication
  • Reasons advanced for the suboptimal adherence include lack of awareness or treatment, increased number of prescribed medications, and major adverse effects of the prescribed drugs
  • Lexaria has so far shown that its DehydraTECH-CBD is not only effective but also well tolerated and is planning to undertake registered clinical trials in pursuit of the FDA’s approval of the drug candidate

A recent research article published in the Journal of the American Heart Association (“AHA”) unearths data that suggests poorly controlled hypertension among both men and women (https://cnw.fm/q4IM3), a problem global innovator Lexaria Bioscience (NASDAQ: LEXX) is keen on solving.

The researchers, who sought to describe gender-differential disease patterns and results of more than 20.6 million emergency department encounters in the United States from 2016 to 2018, made several observations. Firstly, most ED cardiovascular (“CVD”) visits in the sample were due to hypertensive diseases. Secondly, essential hypertension, which is high blood pressure not resulting from other maladies, was the most common CVD diagnosis in women and second most common in men (https://cnw.fm/5powB).

Moreover, the article notes, “Attendances for essential hypertension were more common in women, which may reflect higher rate of preexisting hypertension in women (76.6% vs. 74.4%). These findings may also reflect poorer control of hypertension or poorer access to primary care in women… Further supporting these suppositions, in our sample, although men were less likely to present to the ED with essential hypertension, they were slightly more likely to present with long-term consequences of hypertension-related end-organ damage (hypertensive heart or kidney disease) and were more likely to die following such presentations, suggesting longer duration of exposure to poorly controlled hypertension than women.”

This recent study is one of the latest in a series of research works on uncontrolled hypertension that date back to the 20th century. In a scholarly article published in 2005 in the AHA Journal, for example, researchers observed a high prevalence of uncontrolled hypertension that suggested a significant number of CVD events could be prevented by improved blood pressure control.

“The benefits of pharmacological treatment for [hypertensive] patients are well established. Meta-analysis of randomized placebo-controlled trials indicate that antihypertensive therapy reduces the risk of stroke by approximately 30%, coronary heart disease by 10-20%, congestive heart failure by 40-50%, and total mortality by 10%,” the 2005 research article continues (https://cnw.fm/HcLPN). 

Several other studies have put forth reasons that are thought to cause suboptimal adherence, leading to poor control. These reasons include the lack of awareness or treatment, an increased number of antihypertensive drugs, and major adverse effects, just to mention a few (https://cnw.fm/gJfBD). As this happens, hypertension remains the leading cause of noncommunicable disease deaths globally, raising concerns that have caught the attention of Lexaria, a company developing a potential hypertension treatment with little to no side effects.

The treatment is created by processing cannabidiol (“CBD”) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (“APIs”). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood by as much as 317% but also reduces blood pressure and arterial stiffness.

To put these findings into a more comprehensive context, the company’s 24-person human clinical study, christened HYPER-H21-1, evidenced a rapid and sustained drop in blood pressure. The second study, HYPER-H21-2, a 16-person HCS, showed up to a 23% reduction in overnight blood pressure as well as reduced arterial stiffness, while the third study, HYPER-H21-3, evidenced attenuated pulmonary artery systolic pressure. What the three studies had in common was that no serious adverse events were reported, suggesting that DehydraTECH-CBD is well tolerated (https://cnw.fm/hUxCf).

To further confirm this fact, Lexaria is working toward a planned Phase I(b) trial, expected to commence following the filing of an Investigational New Drug (“IND”) application and the fulfillment of other regulatory requirements. According to the company, the IND-enabling program is currently underway and is expected to be completed later this year or early next year (https://cnw.fm/suz4F).

Lexaria hopes to prove, through registered clinical trials, that its DehydraTECH-CBD formulation has an acceptable safety and tolerability profile and that it is effective against hypertension. The proof could potentially influence the registration of DehydraTECH-CBD as the second FDA-approved CBD drug, offering a reprieve to millions of hypertension patients who do not have their condition under control because they receive numerous antihypertensive drugs or are unwilling to suffer through these medications’ adverse side effects.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Changing Legal Landscape for Cannabis in Colombia and the U.S. Portends a New Era of Productivity for Flora Growth Corp. (NASDAQ: FLGC)

  • Colombia and the United States have both recently exhibited new openness to the possibility of decriminalizing adult recreational cannabis use through legislative change
  • Cannabis supplier Flora Growth cultivates its product at a key Colombian farm and provides it to international markets, and may see additional opportunities arise as cannabis policies advance in the two countries
  • Flora Growth recently announced completion of its first shipments of high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate supplied to its market in the United States
  • The company also recently reported a 604 percent YOY increase in revenues during the H1 reporting period, with a 547 percent gross profit increase during that period

Cannabis may be approaching a new watershed moment as Colombia pushes for national legalization of adult-use marijuana and the United States’ government undertakes long-anticipated discussion of whether to change the drug’s classification. 

The nearly unanimous approval of legislation to legalize and regulate adult-use cannabis by an initial committee reviewing bills in Colombia’s legislature, coupled with the president’s criticisms of decades-long prohibitionist policies and regulatory advances made by his predecessor, position the fertile country with a storied history on the front lines of the global war on drugs to become a major legal producer of cannabis and its derivatives (https://cnw.fm/LcEd8). 

In the United States, the President recently issued executive pardons to criminals convicted of marijuana possession in federal cases and asked federal health and law enforcement agencies to take a fresh look at the possibility of ending marijuana’s classification as an illicit substance, creating energy for cannabis stocks in the country (https://cnw.fm/6gRIf).

International cannabis company Flora Growth (NASDAQ: FLGC) is headquartered in Fort Lauderdale, Florida but operates its cultivation from a 100-hectare (about 247-acre) licensed farming facility in northern Colombia where it develops cannabis products and then ships them into international markets or to its GMP-certified facility in the nation’s capital for transformation into consumer ready goods. 

The company’s NASDAQ listing precludes it from participating in the U.S. domestic market for adult-use cannabis at present, where marijuana has enjoyed some approval on a state-by-state basis despite the federal prohibitions.

But the continually developing approach to recreational cannabis use in Colombia and the United States portends possible new opportunities for the company beyond its current low-cost operation supplying THC and CBD flower and derivatives to international markets and the CBD it provides to its own product supply chain. 

“We are proud to help increase access to safe, legal CBD and THC to consumers all over the globe,” Flora Growth Chairman and CEO Luis Merchan stated last month after the company announced completion of its first exports to of high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate supplied to its market in the United States (https://cnw.fm/gszmr).

Investors have taken a wary approach to cannabis stocks amid ongoing global economic turmoil continuing beyond the immediate impact of the COVID pandemic. But financial data reported by Flora Growth indicates the company has reason for optimism that its strategic advances are taking it in the right direction. 

Flora’s most recent revenue report states that revenues increased 604 percent increase YOY during the H1 period and 117 percent of the previous half-year report (https://cnw.fm/uYeSp).

“Our gross profit increased 547 percent over that same period last year and we expect our revenues for the full year to grow between 300 and 400 percent for … 2022,” Merchan said as part of the management’s analysis of the results. “Despite (COVID-related challenges and economic uncertainty), Flora business units continue to improve their performance.” 

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Companies Scramble to Adapt as Marijuana Legalization Spreads

As more states across the United States establish legal marijuana markets, employers are scrambling to adjust to this new reality. This is because the traditional no-tolerance policies are becoming harder to enforce in the face of the changes brought by legalization.

For instance, there is a current shortage of workers, particularly for lower-paying job opportunities. Pre-employment testing for marijuana is increasingly being seen as a barrier to getting even the few applicants interested in joining the workforce. Many companies are therefore suspending such pre-employment tests especially for jobs which aren’t safety sensitive, such as operating machinery or driving trucks.

The shift away from pre-employment cannabis testing doesn’t however mean that companies are doing away with marijuana testing. For example, Dave Clark, while still CEO of Amazon, wrote in a blog post that the company would no longer reject applicants on the basis of failing a cannabis test. However, the firm would still conduct drug tests after every safety incident or accident that occurs in order to establish whether the party involved was impaired.

Some employers are also expressing concerns about the possible effect on insurance premiums when they stop testing for marijuana before hiring employees and conducting routine tests for the substance on existing employees.

However, Mark Pew, a Georgia-based insurance expert focusing on workers’ compensation, says that it is unlikely that insurers will slap companies with bigger premiums just because those entities are no longer conducting marijuana tests. Rather, premiums could creep up if insurance firms notice that claims are increasing among companies with less stringent drug testing policies in comparison to those that conduct rigorous testing.

The tests themselves have faced some criticism since most test for the presence of THC metabolites in the sample (blood, urine, saliva or hair follicle) tested. A positive test therefore isn’t irrefutable proof that someone was impaired on the job. Rather, the test just confirms that the person used marijuana at some point in the past, and they may or may not have been impaired at the time of the safety incident. Better tests are needed to establish cannabis impairment in a way that can stand court scrutiny.

That notwithstanding, a broader trend of safer workplaces may make it harder to establish whether looser testing policies result in more work-related accidents. Statistics show that there are fewer accidents at work today compared to the frequency of such incidents in the years gone by.

As marijuana and other allied products from various manufacturers like Advanced Container Technologies Inc. (OTC: ACTX) grow in popularity, employers are likely to continue tweaking their drug use policies so that they are more in tandem with current realities.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Courts May Help Bring Federal Marijuana Legalization Closer

Despite President Joseph Biden having pardoned individuals convicted of simple cannabis convictions, he has shown no interest in loosening the federal restrictions that have left most states in control of developing how the billion-dollar marijuana industry in the country is growing. Thus far, 37 states in the country have legalized medical cannabis, with 19 of those states permitting individuals aged 21 and above to possess the drug for recreational use. However, the drug’s illegality at the federal level continues to prevent interstate sales.

Various states have established their marijuana programs to meet objectives beyond legalization. For instance, many prioritize issuance of licenses to those impacted by the war on drugs and entrepreneurs of color.

Courts in the country may have to force their hand in a way that could undermine efforts that diversify this burgeoning industry. For example, a federal court recently ruled that residency requirements on trade imposed in states is unconstitutional because these requirements also endanger packaging and testing rules, which help improve public safety.

Experts believe that this justification by the First Circuit Court of Appeals may open up commerce between different states across the country. An expert on drug laws and federalism, Robert Mikos stated that this ruling foreshadowed the emergence of a national marijuana market, noting that changes in state export and import bans could soon be observed.

The First Circuit is not the only court to rule against residency requirements either. Last year, a federal court in Missouri came down against the residency requirement for ownership in medical cannabis firms imposed in the state.

Various states have also begun to prepare for a potential national market for cannabis. For example, Gov. Gavin Newsom of California recently signed a measure that would permit the state to enter into agreements with other states to regulate the export and import of marijuana products. In 2019, the state of Oregon also approved a similar legislation. The state of New Jersey is expected to go down this path soon.

The path the courts are expected to follow is supported by many advocates who have argued that the time for Congress to amend federal marijuana policies so they can reflect the current legalization landscape is past. This is despite the fact that Congress has the power to regulate global as well as interstate commerce, as stipulated in the Commerce Clause of the U.S. Constitution. At the moment,  however, the legalization of cannabis has mainly been dealt with at the ballot through state measures by voters.

If the courts keep making decisions that open more space for the cannabis industry to operate nationally, federal reform may not be far behind, and entities such as REZYFi Inc. could find themselves swamped with more clients than they had expected to serve in the foreseeable future.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi, Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Federal Labor Secretary Promises to Assist Those Pardoned for Cannabis Crimes Find Jobs

Last week, a pair of cabinet members in the Biden administration discussed the president’s new marijuana initiative. Cabinet members and legislators, as well as advocates and state officials, have widely praised President Joseph Biden for his action.

Marty Walsh, U.S. Labor Secretary, stated in an interview with Yahoo Finance that officials were working hard to make sure that individuals who received pardons for federal cannabis offenses under the decree made by President Biden weren’t hindered from employment opportunities in the future. Walsh explained that the Department of Labor was focused on ensuring that what the president said was carried out, noting that individuals of color made up a disproportionate fraction of those who had been criminalized over marijuana.

Walsh, the former mayor of Boston, had opposed the ballot measure introduced in 2016 to legalize cannabis in Massachusetts. Walsh also voted against a party plank by the Democratic National Committee that endorsed the initiative.

Last week Biden observed the workforce implications of marijuana convictions, noting that thousands of individuals who had been convicted of simple possession who may have been denied housing, educational or employment opportunities as a result of their conviction, would be granted relief under his edict. Separately, Xavier Becerra, secretary of the Department of Health and Human Services, also discussed Biden’s directive to agencies to carry out an administrative review of marijuana’s scheduling status. The health secretary stated that officials would work as fast as they could to finish the analysis, which would probably result in a recommendation to de-schedule or reschedule cannabis.

Becerra added that he’s already spoken to FDA Commissioner Robert Califf about starting the process. Becerra also stated in a tweet that he anticipated working with U.S. Attorney General Merrick Garland to answer the president’s call to action to review how cannabis was scheduled federally.

A spokesperson for the Department of Justice also stated that the department would quickly administer the president’s proclamation, which pardoned people who engaged in simple cannabis possession by restoring the civil, political and other rights of individuals convicted of this particular offense.

Further, Rahul Gupta, director of the White House Office of National Drug Control Policy, praised Biden’s decree, observing that it was clear that the currently used cannabis laws hadn’t worked and a new approach was needed.

The comments of support from agency officials show that the Biden administration is keen on following through on the reform that was announced, with roughly a month left to Election Day.

These social justice efforts are part of what the marijuana industry and entities such as Flora Growth Corp. (NASDAQ: FLGC) have longed to see being implemented so that the country can move on and heal from the adverse effects of prohibition.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Biden Health Secretary Tasked FDA to Move Quickly on Cannabis’ Scheduling Review

Xavier Becerra, the U.S. Health & Human Services Secretary, revealed during a Meet & Greet event in Tampa, Florida, that his agency is prepared to move quickly to implement the review of marijuana’s status as a Schedule 1 drug. This comes after President Joe Biden issued a directive ordering that the scheduling of marijuana in the Controlled Substances Act be reviewed.

Speaking to reporters, the health secretary asserted that the nation will see the speed with which the review will be conducted. However, Becerra was quick to add that at the end of the day, science would be the deciding factor regarding the conclusions of the review process.

The directive calling for a review of the categorization of marijuana was one of the announcements that the president made last week. He also announced that the federal government was going to pardon all those convicted in federal court for simple cannabis possession. The Justice Department was tasked with designing mechanisms through which these pardons would be granted. Biden then called on governors around the country to emulate this step and also consider granting pardons to those with minor cannabis-related convictions.

Becerra revealed that the job of conducting the review per the president’s order will go to the U.S. Food & Drug Administration. The HHS secretary said he had already talked to Commissioner Robert Califf of the FDA about starting the review process. Becerra then commented that while conducting such a review wasn’t a new thing, the amount of information to collect is significant because so many states have implemented medical or recreational marijuana programs over the years.

At the moment, a total of 19 states have recreational or adult-use marijuana markets while an additional five will decide whether to legalize recreational cannabis during the upcoming polls in November. Another 18 states also have medicinal cannabis programs.

Despite this wave of marijuana legalization across the country, most financial institutions are reluctant to accept marijuana businesses as clients for fear that they will face the wrath of federal authorities; federal policy maintains that cannabis is strictly prohibited and doesn’t have any known medical application.

The entire cannabis industry, including actors such as Prime Harvest Inc., will probably be waiting with bated breath to see how quickly the scheduling review is conducted and what recommendations will be made for implementation by the federal government. Hopefully, the process will not drag on endlessly for years.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients, developed the patented DehydraTECH(TM) drug delivery technology. “The company has evidenced, through in-vivo, in-vitro and pre-clinical testing, that DehydraTECH delivers more APIs at a faster rate than controls, enabling more effective drug absorption. The testing has so far involved APIs such as cannabidiol (‘CBD’), PDE5 inhibitors, antiviral drugs, and nicotine, each at different stages of product development. This DehydraTECH pipeline, Lexaria says, is addressing severe unmet patient needs. Its DehydraTECH-CBD compound, for example, specifically targets the hypertension space,” reads a recent article. “In the U.S., about 47% of adults, or 116 million people, have hypertension, with only about 24% having the condition under control, while globally, hypertension affects more than 1 billion people, or about 30% of the adult population… Heightened blood pressure has several consequences, including the fact that it makes arteries less elastic, effectively damaging them. This damage, in turn, decreases the blood flow and oxygen to the heart, leading to heart disease. The decreased blood flow also increases the risk of stroke. In extreme cases, hypertension causes death.”

To view the full article, visit https://cnw.fm/sc0lX

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – SHF Holdings Inc. (NASDAQ: SHFS) Continues Trading on the Nasdaq After Successful Business Combination

SHF Holdings (NASDAQ: SHFS), formerly known as Northern Lights Acquisition Corp. (“NLIT”), a special purpose acquisition company, recently completed its acquisition of SHF LLC, d/b/a Safe Harbor Financial, a leader in offering compliance services to financial institutions that serve the regulated cannabis industry. With the transaction now complete, the company has changed its name to “SHF Holdings Inc.,” with its Class A Common Stock and warrants continuing to trade on the Nasdaq Capital Market. “With its established leadership position in cannabis-related compliance services and continued growth in its financial institution clients, this is an exciting time for Safe Harbor to become part of a Nasdaq-listed company,” said John Darwin, co-CEO of NLIT prior to the closing.

To view the full press release, visit https://cnw.fm/2tr2y

About Northern Lights Acquisition Corp.

The company was formed as a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. For more information, visit https://NorthernLightsAcquisitionCorp.com.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lift&Co. Expo Cannabis Business Conference & Trade Show Releases Limited All-Access Presale Tickets for Vancouver 2023

Canada’s leading Cannabis Conference and Trade Show, Lift&Co. Expo, invites all members of the cannabis industry and community to its upcoming Vancouver event taking place January 12-14, 2023, at the Vancouver Convention Centre. For a limited time, Lift&Co. Expo is releasing a limited number of discounted Lift Cannabis Business Conference (“LCBC”) + Expo All-Access presale tickets for $350 (regularly priced at $599).

Starting on day one, the Lift Cannabis Business Conference will tackle timely industry topics such as cannabis blockchain, brand and retailer relations, and cannabis real estate investing. It will also explore laws and regulations that need to change in time with the government review at the end of 2022.

New voices anticipated at the conference include Dr. Everton Flemmings, Founder & President of iValley Nutraceuticals; and David Goldstein, CEO of Stoke Inventory Partners. Also sharing their invaluable knowledge and insight are leading industry experts such as Jaclynn Pehota, Executive Director of The Retail Cannabis Council of Canada and George Smitherman of The Cannabis Council of Canada.

Continuing on days two and three, the Expo will showcase 200+ exhibiting companies from across the full “seed to sale” spectrum in a high-energy setting. In addition, the event is legendary for its networking opportunities, offering attendees the chance to establish ties among businesses, traders, vendors, cultivators, and more. 

Indeed, ever-growing audiences join in every year to be a part of this larger-than-life event that sees packed houses and a well-planned agenda. The experience at the Lift&Co. Expo is unmatched, with scintillating music, unending conversations and the free exchange of ideas. Plush amenities include multiple lounge areas, interactive booth set-ups and premium partner hotels, just to name a few.  

The presale LCBC ticket and all-access pass includes:

  • Exclusive access to Lift Cannabis Business Conference 
  • Complimentary morning and afternoon breaks and lunch
  • Industry networking reception 
  • Full access to the Exhibit Hall showcase of more than 200+ companies 
  • Full access to Exhibit Hall programming, including speakers, panels and demonstrations 
  • Full access to the new Brand Discovery Pavilion and Retailer Zone
  • Exclusive ticket to the Lift&Co. Expo After Party 

Attendees can visit the Lift&Co. Expo website to secure their presale ticket, for a limited time only.

To learn more, please visit https://liftexpo.ca/lift-co-expo-vancouver-2023/

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Patented DehydraTECH(TM) Technology to Fight America’s Silent Killer – Hypertension

  • Three out of four adults living with hypertension do not have the condition under control, putting them at risk for other serious complications
  • Lexaria’s proposed therapy for hypertension is the highly efficient DehydraTECH-CBD, which has presented with no serious adverse side effects in test participants
  • Dominated by the North American market, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026

In the United States, over 121.5 million adults are affected by high blood pressure – with statistics stacked against people of color, those with a family history of high blood pressure, heart disease, stroke, or kidney disease, and women who experienced blood pressure problems during pregnancy. According to the American Heart Association, high blood pressure is defined as a systolic pressure of 130 or higher and a diastolic pressure of 80 or higher that stays high over a period of time (https://cnw.fm/dbCLN).

For some, managing high blood pressure is as simple as changing daily habits or being proactive about monitoring it if there is a history or predisposition to the disease. Early detection can protect the brain, reducing the risk of stroke, dementia, and other vascular diseases that affect the brain. Although high blood pressure is not the only risk factor associated, being conscious of it can help preserve the brain’s blood vessels. Unfortunately, three out of four adults do not have their high blood pressure under control, creating an unmet need in the hypertension treatment market.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to address the unmet needs of adults with high blood pressure (hypertension). DehydraTECH is a patented drug delivery technology that improves the oral administration of Active Pharmaceutical Ingredients (“APIs”). The benefits of using DehydraTECH-enabled APIs include the following:

  • Improvement of onset speed – effects of the drug are felt in minutes
  • Masked unwanted tastes – eliminates the need for sugar-filled edibles
  • Increased bioavailability – the technology is more effective at delivering the drug into the bloodstream
  • Increased brain absorption – testing has seen up to 27x improvement in the amount of the drug crossing the blood-brain barrier
  • Reduction in drug administration costs – the higher ratio of the drug being delivered is expected to lower the overall costs of administration

Lexaria’s initial focus on hypertension has been its DehydraTECH-CBD, which is currently in the IND enabling studies phase and is actively developing lead product pipeline candidates. The advanced hypertension program has delivered positive results with no serious adverse effects, with the most recent being completed in 2021, with 16 participants exhibiting a reduction of attenuated pulmonary artery systolic pressure of approximately 5 mmHg, or 41% overall, in male participants. The company’s corporate presentation lists all of the results – from 2018-2021 (https://cnw.fm/0by1r). Results are pending from Lexaria’s largest ever human clinical trial, where dosing completed in July.

According to Allied Market Research, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026, growing at a CAGR of 3.1% from 2019 to 2026. North America dominates the majority of the drug market. The market’s growth is expected due to the prevalence of hypertension across the globe and the interest in maintaining healthier lifestyles in the wake of the COVID-19 pandemic (https://cnw.fm/5vqaT). 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.